Aurobindo Pharma gains after subsidiary gets US FDA nod for corticosteroid

6 Jul 2022 , 01:13 PM

In an exchange filing made during market hours today, the company said that its wholly owned subsidiary Eugia Pharma Specialities has received a final approval from the US Food & Drug Administration (US FDA) to manufacture and market Triamcinolone Acetonide Injectable Suspension. Triamcinolone Acetonide Injectable Suspension would be bioequivalent and therapeutically equivalent to the reference listed drug (RLD) Kenalog-40 Injectable Suspension of Bristol-Myers Squibb Company. The product is being launched this month. The approved product has an estimated market size of around $73 million for the twelve months ending May 2022, according to IQVIA. This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products. Triamcinolone Acetonide Injectable Suspension is in therapeutic Category of Synthetic glucocorticoid corticosteroid and indicated for the treatment of intramuscular and intra-articular use. Aurobindo Pharma develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. The companys consolidated net profit declined 28.1% to Rs 576.46 crore on a 3.3% fall in net sales to Rs 5,795.34 crore in Q4 FY22 over Q4 FY21.Powered by Capital Market – Live News